Sofosbuvir / Velpatasvir

Famotidine

Administration time adjustment is recommended.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Famotidine by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of velpatasvir .

Sofosbuvir / Velpatasvir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy.

Alternative solution(s)

Famotidine

Pharmacodynamic effects

Recommendations

Administrer at the same time and/or 12 hours after the combined drug.

Recommended dosage : dose not exceeding famotidine 40 mg twice daily or equivalent.

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir
3250 3250
60 60
- -
400/100 mg 400/100 mg
QD QD
- 18%/- 19% † - 20%/- 15% ††
- 8%/- 20% † - 23%/- 13% ††
Famotidine
3250 3250
60 60
- -
40 mg 40 mg
x 1 * x 1 **
   
   
Comment

Ref #3250 :
* At the same time than sofosbuvir/velpatasvir;
† GS-331007 : AUC -6%; Cmax -16%;
** 12 hours after sofosbuvir/velpatasvir;
†† GS-331007 : AUC +4%; Cmax +20%.

Reference
  • 3250
    Sofosbuvir/Velpatasvir (Epclusa), Gilead Sciences, Ontario, Canada, 16 avril 2018.
  • 3270
    Mogalian E et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed dose combination. 51st Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 13-17, 2016. Abstract FRI-168.